Maravai LifeSciences Holdings, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Maravai LifeSciences Holdings, Inc. (MRVI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.45 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- Maravai LifeSciences Holdings, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $2.45.
- Maravai LifeSciences Holdings, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $14.76, a 38.01% decline from fiscal 2022.
- Maravai LifeSciences Holdings, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $23.81, a 40.45% decline from fiscal 2021.
- Maravai LifeSciences Holdings, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $39.98.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $2.45 10-K · filed 2026-02-26 |
| 2023-12-31 | $14.76 10-K · filed 2024-02-29 |
| 2022-12-31 | $23.81 10-K · filed 2023-02-28 |
| 2021-12-31 | $39.98 10-K · filed 2022-03-01 |